Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD

Bone Marrow Transplantation

Volumn 45, Issue 4, 2010, Pages 662-667

  Gergis, U ^a   Markey, K ^b   Greene, J ^b   Kharfan Dabaja, M ^b   Field, T ^b   Wetzstein, G ^b   Schell, M J ^b   Huang, Y ^b   Anasetti, C ^b   Perkins, J ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

GVHD; Hematopoietic cell transplant; Invasive fungal infections; Voriconazole

Indexed keywords

FLUCONAZOLE; GLUCOCORTICOID; ITRACONAZOLE; PREDNISONE; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIFUNGAL AGENTS; CHEMOPREVENTION; FEMALE; FLUCONAZOLE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 77950629027     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.210     Document Type: Article

References (22)

1. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5: 55-68.
2. Wald A, Leisenring W, van Burik J-A, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
3. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.
4. Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36: 9-15.
5. Parody R, Martino R, Rovira M, Vazquez L, Vá zquez MJ, de la Cámara R et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006; 12: 734-748.
6. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Eng J Med 1992; 326: 845-851.
7. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-340.
8. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation- a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
9. Marr KA, Seidel K, Slavin M, Bowden RA, Schoch HG, Flowers ME et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasisrelated death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
10. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-713.
11. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
12. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
13. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109, 496) and four other antifungal agents against 394 clinical isolates of Candida sp. Antimicrob Agents Chemother 1998; 42: 161-163.
14. Purkins L, Wood N, Ghahramani P, Greenleigh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553.
15. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395-402.
16. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic. stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
17. Marubini E, Valsecchi MG. Analyzing Survival Data from Clinical Trials and Observational Studies. John Wiley & Sons Ltd: Chichester, UK, 1995.
18. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1140-1154.
19. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
20. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning. Blood 2003; 102: 823-833.
21. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
22. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID et al. Results of a randomized, double-blind trial of fluconazole vs voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood 2007; 110: 163 (abstract).